Breast carcinomas remain one of the most common forms of cancer among women. Likewise, mammary cancers are one of the leading causes of death in dogs. Among the principal challenges in tumor therapies, resistance to cytotoxic therapeutics represents a major bottleneck in the fight against cancer. The development of novel delivery methods for nitric oxide has fueled the re-emergence of nitric oxide as a potential adjuvant for enhancing sensitivity of cancer cells to traditional therapeutics. More importantly, when delivered under the right conditions, nitric oxide exhibits the capacity to reduce or altogether halt tumor cell proliferation. Here, we present a new class of nitric oxide-releasing pro-drugs using non-cytotoxic S-nitrosothiol nitric oxide donors to deliver nitric oxide in a controlled manner to halt the growth of both human breast and canine mammary carcinoma cells.
Introduction
Chemotherapeutic resistance and dose-limiting toxicity are critical limiting factors among current clinical practices for managing human breast and canine mammary cancers [1, 2] .
These limitations have been the impetus for dozens of studies related to adjuvant therapies designed to enhance the tumordirected cytotoxicity of chemotherapeutics. Among them, nitric oxide (NO) donors have emerged as some of the most promising adjuvants of current therapies [3, 4] . Moreover, the development of controlled release NO pro-drugs have revealed the capacity of NO donors to function independently of chemotherapeutics in halting the proliferation of cancer cells [5] [6] [7] .
The signal transduction capacity of NO plays a central role in cell regulatory pathways [8, 9] and is essential in the mediation of leukocytic cytotoxicity via superoxide [10] [11] [12] [13] . The physiological processes which depend upon NO vary in the concentrations of NO that they require. For example, while NOinduced cytotoxicity requires high, precipitous concentrations [13] , regulation of platelet accretion is governed by specific localization of exacting concentrations of nitric oxide [14, 15] .
Consequently, several isoforms of NO synthase (NOS) which vary in their expression patterns and rates of productivity are responsible for the synthesis of nitric oxide under varying conditions. These employ the common substrate, L-arginine, and include: 1) neuronal NOS (nNOS), a calcium dependent form which plays a signaling role in the central nervous system (CNS);
2) endothelial NOS (eNOS), another calcium dependent form involved in cell signaling outside the CNS; and 3) inducible NOS (iNOS), an inducible form with a propensity for producing rapid, high concentration bursts of NO involved in immunological responses [16, 17] .
In vivo, NO has been shown to have a significant role in the control of immunological mechanisms targeting tumors [18] [19] [20] . Likewise, numerous in vitro studies have implicated a role for NO in the induction of apoptosis in cancer cells via impacts on mitochondrial permeability and subsequent release of cytochrome c oxidase [21, 22] . A thorough evaluation of the many biological pathways impacted by NO, the concentrations required to elicit those impacts, and the donors capable of releasing the required concentrations in a temporally controlled, targeted way will reveal a novel line of highly effective cancer therapeutics.
The role of iNOS-derived NO in cytotoxicity has generated broad interest in the capacity of NO donors to function in the treatment of cancer. Given the breadth of physiological outcomes imparted by NO derived from each NOS, it is clear that timing, longevity, and intensity of NO release are deciding factors in the biological consequences imparted by its presence. In considering potential NO donors for anticancer applications, an understanding of variations among these factors, as imparted by NO derived from iNOS versus nNOS and eNOS has yielded much insight. The effects of nNOS and eNOS are elicited by comparatively minute concentrations of NO produced for relatively short durations [23] . These are typically in the range of nanomolar concentrations and seconds in duration, respectively [24, 25] . In the case of iNOS, concentrations of NO are produced on a much higher scale [24] [25] [26] . These variations in the intensity of NO exposure appear to differentiate between events involved in cell signaling (nNOS; eNOS) and events impacting cell proliferation and survival (iNOS). Thus, donors of exogenous NO for potential use in cancer therapy must be designed to more closely model the release of NO as exhibited by iNOS [27, 28] .
Although many NO donors have been studied for their anti-cancer properties, toxicity of the NO carrier, cellular uptake, and controlled release kinetics have limited their ultimate success. For example, Stevens et al. showed that NO-releasing diazeniumdiolated silica nanoparticles inhibited the growth of ovarian tumor cells; however, the non-diazeniumdiolated silica nanoparticles (AHAP3-silica) exhibited significant cytotoxicity because of the primary amines on the silica surfaces [29] . In this report, we describe a new class of NO-releasing pro-drugs using non-cytotoxic S-nitrosothiol NO donors which deliver NO sitespecifically and in a controlled manner. The NO-releasing prodrugs evaluated herein are polysaccharide based dextran thiomers prepared via a covalent incorporation of an NO-donor ( Figure 1 ) [30] . Because of the enhanced transport of saccharides in tumor and cancer cells [31] , an increased uptake of this NOdonor is anticipated over previously reported NO-donors.
Moreover, stabilization of the donors against rapid and uncontrolled release of NO provides a stable pro-drug to release NO quantitatively under physiological conditions. Preparation of NO-releasing dextran pro-drugs: NO-releasing Snitrosated dextran derivatives were prepared following our earlier reported method [30] . Briefly, Dextran (from Leuconostoc spp., M r ~40,000, Sigma-Aldrich, St. Louis, MO) was carboxymethylated using monochloroacetic acid followed by conjugation with the amine group of cysteine using carbodiimide chemistry. The thiolated dextran derivatives were S-nitrosated using t-butyl nitrite in anhydrous methanol protected from direct exposure to light. All intermediates and final products were characterized using 1 H NMR, Ellman's assay (for thiol quantification), UV (for S-nitrosation reaction monitoring and quantification), and GPC (for molecular weight profile) [30] . NO Release Assay: The NO release assays were performed as previously described [30] .
Materials and Methods
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Results
We measured the controlled release of NO from a polysaccharide based dextran thiomer (dextran-cysteine NO donor) [30] and evaluated its impact on the proliferation of canine mammary carcinoma cells (CMT12). The NO donor was chosen based on its capacity to produce a stable pro-drug to release a rapid, high concentration burst of NO as exhibited by iNOS [16, 17] under physiological conditions. The polysaccharide basis was chosen over a monosaccharide for its superiority in drug delivery applications including the improvement of microcirculatory flow through decreased viscosity of blood and inhibition of erythrocytic aggregation due to its colloidal nature. To measure NO release performance, the release of NO from the dextrancysteine NO donor was measured over a 180 minute time interval (Figure 2) . The dextran-cysteine release profile can be described as an initial rapid rate of release, reaching a maximum release rate which gradually plateaued until a baseline level of 0.00062 mmol was achieved. To evaluate the impacts of NO released by the dextrancysteine NO donor on canine mammary carcinoma cells, CMT12 cells were exposed to either the dextran-cysteine NO donor or a dextran-cysteine control and growth assays were run to 36h. Donor sample size was based on the amount of donor required to reach baseline (as above) in 10ml media/sample. There was no statistical significance between growth rates of NO-treated versus control-treated cells at 12 or 24 hours. However, at 36h, CMT12 cells exhibited a marked reduction of growth in the presence of NO donor relative to the control ( Figure 3A) . Moreover, those samples which were exposed to the NO donor exhibited a significant increase in cell death between 24 and 36h.
In recent years, canine neoplasias have served an increasing role as models for designing human cancer therapeutics. Given the significance of the impacts of the dextrancysteine NO donor on canine mammary carcinoma cells, we also evaluated the impact of the NO donor on a human breast carcinoma line (MCF-7). As observed with CMT12 cells, there was no statistical significance between growth rates of NO-treated versus control-treated MCF-7 cells at 12 or 24 hours. However, at 36h, MCF-7 cells exhibited a marked reduction of growth in the presence of NO donor relative to the control ( Figure 3B ).
Interestingly, those samples which were exposed to the NO donor failed to exhibit a significant increase in cell death as had been observed in the canine mammary carcinoma cells. independently as anticancer therapeutics [5] [6] [7] . In all cases, it is clear that such donors must exhibit a modestly controlled release at high concentrations to be effective against tumors. Given the disparity in physiological outcomes of NO treatments in varying cancer cells, additional information is required related to the specific tumor cell types that may be best suited as targets of NO therapy.
Our NO release assays confirm that polysaccharide based dextran thiomers can be used to produce a stable pro-drug to release a rapid, high concentration burst of NO quantitatively under physiological conditions. Further, our growth assays indicate that NO donors have potential in serving as the basis for therapeutic applications in the treatment of both canine and human breast carcinomas. We attribute this largely to the enhanced transport of saccharides in cancer cells [31] , resulting in an increased uptake of the NO-donor in the target cells. 
